TheraRadar

Competitive Landscape by Indication

Data updated: Nov 12, 2026

160 indications, 120,230 trials mapped

Oncology

56,582 trials
Solid Tumor (Advanced)
9843 trials 901 Ph3
Merck, Sichuan Baili Pharmaceutical Co., Ltd., GSK
Breast Cancer
4059 trials 725 Ph3
AstraZeneca, Roche, Pfizer
Non-Hodgkin Lymphoma
4010 trials 362 Ph3
Merck, Roche, AstraZeneca
NSCLC
3537 trials 578 Ph3
AstraZeneca, Merck, Sichuan Baili Pharmaceutical Co., Ltd.
Colorectal Cancer
2692 trials 381 Ph3
AbbVie, AstraZeneca, Revolution Medicines, Inc.
Prostate Cancer
2357 trials 361 Ph3
Novartis, AstraZeneca, Jiangsu HengRui Medicine Co., Ltd.
Multiple Myeloma
1977 trials 245 Ph3
Johnson & Johnson, GSK, AbbVie
AML
1854 trials 177 Ph3
AbbVie, Taiho Oncology, Inc., Kura Oncology, Inc.
Hematologic Malignancies
1749 trials 154 Ph3
Johnson & Johnson, Novartis, Merck
Melanoma
1690 trials 143 Ph3
Bristol-Myers Squibb, Merck, Regeneron
Pancreatic Cancer
1641 trials 142 Ph3
Revolution Medicines, Inc., Astellas, AstraZeneca
Hepatocellular Carcinoma
1461 trials 224 Ph3
AstraZeneca, Akeso, Roche
Ovarian Cancer
1425 trials 171 Ph3
AstraZeneca, AbbVie, Merck
Lung Cancer (General)
1348 trials 173 Ph3
Chongqing Precision Biotech Co., Ltd, AstraZeneca, Avistone Biotechnology Co., Ltd.
Head and Neck Cancer
1286 trials 117 Ph3
Sichuan Baili Pharmaceutical Co., Ltd., AstraZeneca, Genmab
MDS
1207 trials 100 Ph3
Bristol-Myers Squibb, Takeda, Taiho Oncology, Inc.
Gastric Cancer
1134 trials 186 Ph3
AstraZeneca, Astellas, Chongqing Precision Biotech Co., Ltd
Sarcoma
1075 trials 75 Ph3
USWM CT, LLC, Eli Lilly, Novartis
Bladder Cancer
1018 trials 145 Ph3
Merck, AstraZeneca, Pfizer
Glioblastoma
997 trials 66 Ph3
Novartis, GT Medical Technologies, Inc., Philogen S.p.A.
ALL
961 trials 94 Ph3
Novartis, Amgen, Chongqing Precision Biotech Co., Ltd
Esophageal Cancer
824 trials 135 Ph3
AstraZeneca, Merck, Pfizer
Brain Tumor
809 trials 58 Ph3
Nuvation Bio Inc., InSightec, Jazz Pharmaceuticals
Renal Cell Carcinoma
800 trials 74 Ph3
Merck, Exelixis, Bristol-Myers Squibb
CLL
792 trials 84 Ph3
BeOne Medicines, Acerta Pharma BV, AbbVie
Squamous Cell Carcinoma
675 trials 68 Ph3
Regeneron, Merck, AstraZeneca
Cholangiocarcinoma
621 trials 64 Ph3
AstraZeneca, Suzhou Suncadia Biopharmaceuticals Co., Ltd., Eli Lilly
Triple Negative Breast Cancer
619 trials 72 Ph3
Gilead, Novartis, AstraZeneca
SCLC
585 trials 78 Ph3
Amgen, Boehringer Ingelheim, Merck
Cervical Cancer
539 trials 90 Ph3
AstraZeneca, Merck, Shanghai Bovax Biotechnology Co., Ltd.
Hodgkin Lymphoma
488 trials 37 Ph3
Merck, Takeda, Tessa Therapeutics
Endometrial Cancer
480 trials 52 Ph3
AstraZeneca, Merck, Genmab
CML
407 trials 46 Ph3
Novartis, Shenzhen TargetRx Co., Ltd., Jiangsu Hansoh Pharmaceutical Co., Ltd.
Neuroendocrine Tumors
331 trials 43 Ph3
Advanced Accelerator Applications, Crinetics Pharmaceuticals Inc., Merck
Myelofibrosis
288 trials 35 Ph3
Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Novartis, Bristol-Myers Squibb
Mesothelioma
286 trials 18 Ph3
Novartis, AstraZeneca, Vivace Therapeutics, Inc
Thyroid Cancer
237 trials 36 Ph3
Exelixis, Eli Lilly, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
HER2+ Breast Cancer
197 trials 35 Ph3
Sichuan Baili Pharmaceutical Co., Ltd., Roche, Jazz Pharmaceuticals
HER2- Breast Cancer
181 trials 20 Ph3
AstraZeneca, Novartis, BeOne Medicines
Merkel Cell Carcinoma
102 trials 6 Ph3
TuHURA Biosciences, Inc., ImmunityBio, Inc., Novartis

CNS

10,666 trials
Major Depression
1804 trials 484 Ph3
Neurocrine Biosciences, Johnson & Johnson, Xenon Pharmaceuticals Inc.
Alzheimer's Disease
1558 trials 297 Ph3
Eli Lilly, Bristol-Myers Squibb, Roche
Schizophrenia
959 trials 259 Ph3
Neurocrine Biosciences, Luye Pharma Group Ltd., Bristol-Myers Squibb
Parkinson's Disease
954 trials 176 Ph3
iRegene Therapeutics Co., Ltd., Roche, Luye Pharma Group Ltd.
Multiple Sclerosis
876 trials 235 Ph3
Roche, Novartis, Sanofi
Migraine
528 trials 200 Ph3
Pfizer, AbbVie, H. Lundbeck A/S
Anxiety
479 trials 111 Ph3
Intra-Cellular Therapies, Inc., Otsuka Pharmaceutical Development & Commercialization, Inc., Beijing Union Pharmaceutical Factory Ltd
Epilepsy
478 trials 171 Ph3
Praxis Precision Medicines, Rapport Therapeutics Inc., Biohaven Therapeutics Ltd.
Alcohol Use Disorder
453 trials 73 Ph3
Eli Lilly, Pop Test Oncology LLC, Newleos Therapeutics, Inc.
Opioid Use Disorder
434 trials 92 Ph3
Go Medical Industries Pty Ltd, Akyso Therapeutics, LLC, Eli Lilly
ALS
360 trials 72 Ph3
Eli Lilly, Biogen, Amylyx Pharmaceuticals Inc.
Autism Spectrum Disorder
342 trials 66 Ph3
Intra-Cellular Therapies, Inc., Bristol-Myers Squibb, Curemark
ADHD
342 trials 122 Ph3
Otsuka Pharmaceutical Co., Ltd., Axsome Therapeutics, Inc., Bazelet Nehushtan LtD.
PTSD
327 trials 65 Ph3
Oui Therapeutics, Inc., COMPASS Pathways, Senseye, Inc.
Bipolar Disorder
293 trials 96 Ph3
Bristol-Myers Squibb, Intra-Cellular Therapies, Inc., Xenon Pharmaceuticals Inc.
Neuropathy
289 trials 71 Ph3
argenx, WinSanTor, Inc, Rinri Therapeutics
Huntington's Disease
106 trials 18 Ph3
Roche, Skyhawk Therapeutics, Inc., Novartis
OCD
84 trials 11 Ph3
Vericel Corporation, Biohaven Pharmaceuticals, Inc., Roche

Click any indication to see full competitive landscape (all sponsors, trials, phases).

Data: ClinicalTrials.gov | Mapping: Indication Taxonomy